(E/Z)-IT-603

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

(E/Z)-IT-603  纯度: 98.08%

(E/Z)-IT-603 是 E-IT-603 和 Z-IT-603 (IT-603) 的混合物。IT-603 是一种 c-Rel 抑制剂，其 IC50 值为3 μM。IT-603 具有抗癌活性。(E/Z)-IT-603 有望作为调节剂调节移植物抗宿主病和恶性病中的 T 细胞反应。

(E/Z)-IT-603

(E/Z)-IT-603 Chemical Structure

CAS No. : 292168-90-2

规格 价格 是否有货 数量
5 mg ￥3000 In-stock
10 mg ￥4800 In-stock
25 mg ￥9500 In-stock
50 mg ￥14500 In-stock
100 mg ￥22500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

(E/Z)-IT-603 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Pyroptosis Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library

生物活性

(E/Z)-IT-603 is a mixture of E-IT-603 and Z-IT-603 (IT-603). IT-603 is a c-Rel inhibitor with an IC50 of 3 μM. IT-603 has anti-tumor activity. (E/Z)-IT-603 is a promising modulator of T-cell responses in the context of graft-versus-host disease (GVHD) and malignant diseases[1].

分子量

329.17

Formula

C11H9BrN2O3S
CAS 号

292168-90-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (379.74 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.0379 mL 15.1897 mL 30.3794 mL
5 mM 0.6076 mL 3.0379 mL 6.0759 mL
10 mM 0.3038 mL 1.5190 mL 3.0379 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Yusuke Shono, et al. A small molecule c-Rel inhibitor reduces alloactivation of T-cells without compromising anti-tumor activity. Cancer Discov. 2014 May; 4(5): 578-591.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务